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Abstract: BACKGROUND Long-term trends of the incidence and outcome of cardiogenic shock (CS)
patients are scarce. We analyze for the first time trends in the incidence and outcome of CS during a
20-year period in Switzerland. METHODS AND RESULTS The AMIS (Acute Myocardial Infarction
in Switzerland) Plus Registry enrolls patients with acute myocardial infarction from 83 hospitals in
Switzerland. We analyzed trends in the incidence, treatment, and in-hospital mortality of patients with
CS enrolled between 1997 and 2017. The impact of revascularization strategy on outcome was assessed
for the time period 2005 to 2017. Among 52 808 patients enrolled, 963 patients were excluded because of
missing data and 51 842 (98%) patients remained for the purpose of the present analysis. Overall, 4090
patients (7.9%) with a mean age of 69.6±12.5 years experienced acute myocardial infarction complicated
by CS. Overall, rates of CS declined from 8.7% to 7.3% between 1997 and 2017 ( P for trend, <0.001;
1997-2006 versus 2007-2017). We observed a decrease in CS developing during hospitalization from 7.8%
to 3.5% in the period 1997 to 2006 compared with 2007 to 2017 ( P for trend, <0.001), which was partially
offset by an increase in CS on admission between 2006 and 2017 (2.5% [1997-2006] to 4.6% [2007-2017];
P for trend, <0.001). In-hospital mortality declined from 62.2% in 1997 to 36.3% in 2017 ( P<0.001
for temporal trend). Percutaneous coronary intervention was the strongest independent predictor for
survival (odds ratio, 0.36; CI, 0.28-045; P<0.001). Among patients with acute myocardial infarction and
multivessel disease, multivessel percutaneous coronary intervention was associated with an increased risk
of in-hospital mortality (odds ratio, 1.88; 95% CI, 1.59-2.21) and was an independent predictor for the
development of CS during hospitalization (odds ratio, 1.93; 95% CI, 1.62-2.30). CONCLUSIONS Rates
of CS declined between 1997 and 2017 driven by a reduction of CS developing during hospitalization.
In-hospital mortality from CS declined from 62.8% (1997) to <40% (2017). Multivessel percutaneous
coronary intervention was associated with an increased risk of mortality and the development of CS
during hospitalization.
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.118.007293





Hunziker, Lukas; Radovanovic, Dragana; Jeger, Raban; Pedrazzini, Giovanni; Cuculi, Florim; Urban,
Philip; Erne, Paul; Rickli, Hans; Pilgrim, Thomas (2019). Twenty-Year Trends in the Incidence and




Circ Cardiovasc Interv. 2019;12:e007293. DOI: 10.1161/CIRCINTERVENTIONS.118.007293 April 2019 1
Key Words: acute coronary syndrome 
◼ humans ◼ incidence ◼ shock  
◼ Switzerland
BACKGROUND: Long-term trends of the incidence and outcome of 
cardiogenic shock (CS) patients are scarce. We analyze for the first time 
trends in the incidence and outcome of CS during a 20-year period in 
Switzerland.
METHODS AND RESULTS: The AMIS (Acute Myocardial Infarction in 
Switzerland) Plus Registry enrolls patients with acute myocardial infarction 
from 83 hospitals in Switzerland. We analyzed trends in the incidence, 
treatment, and in-hospital mortality of patients with CS enrolled between 
1997 and 2017. The impact of revascularization strategy on outcome 
was assessed for the time period 2005 to 2017. Among 52 808 patients 
enrolled, 963 patients were excluded because of missing data and 51 842 
(98%) patients remained for the purpose of the present analysis. Overall, 
4090 patients (7.9%) with a mean age of 69.6±12.5 years experienced 
acute myocardial infarction complicated by CS. Overall, rates of CS 
declined from 8.7% to 7.3% between 1997 and 2017 (P for trend, 
<0.001; 1997–2006 versus 2007–2017). We observed a decrease in CS 
developing during hospitalization from 7.8% to 3.5% in the period 1997 
to 2006 compared with 2007 to 2017 (P for trend, <0.001), which was 
partially offset by an increase in CS on admission between 2006 and 
2017 (2.5% [1997–2006] to 4.6% [2007–2017]; P for trend, <0.001). 
In-hospital mortality declined from 62.2% in 1997 to 36.3% in 2017 
(P<0.001 for temporal trend). Percutaneous coronary intervention was 
the strongest independent predictor for survival (odds ratio, 0.36; CI, 
0.28–045; P<0.001). Among patients with acute myocardial infarction 
and multivessel disease, multivessel percutaneous coronary intervention 
was associated with an increased risk of in-hospital mortality (odds ratio, 
1.88; 95% CI, 1.59–2.21) and was an independent predictor for the 
development of CS during hospitalization (odds ratio, 1.93; 95% CI, 
1.62–2.30).
CONCLUSIONS: Rates of CS declined between 1997 and 2017 driven by 
a reduction of CS developing during hospitalization. In-hospital mortality 
from CS declined from 62.8% (1997) to <40% (2017). Multivessel 
percutaneous coronary intervention was associated with an increased risk 
of mortality and the development of CS during hospitalization.
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L
ong-term trends of the incidence and outcome of 
cardiogenic shock (CS) patients are scarce. The inci-
dence of CS varies substantially among available 
long-term studies and depends on the region and time 
period studied. Several studies have shown a variable 
decrease in the rates of CS ranging from 1.8% to 1.4% 
between 2000 and 2013 in a study from Israel,1 from 
12% in 1995 to 4% in 20122 or from 3.4% in 1992 to 
2.6% in 2008.3 In summary, a decrease in the incidence 
of CS is generally documented after the late 1990’s.4 
While in the last decade (2001–2011), a relatively stable 
incidence of 3.7%5 and 5.2% has been reported,6,7 2 
recent studies document an increasing incidence of CS 
during the last decade (2003–2010) from 7.9 to 10.1 
in patients ST-segment–elevation myocardial infarc-
tion (STEMI)8 and non-STEMI patients.9 In all studies, a 
consistent decrease of mortality after CS was observed 
since the nineties.3,4,10
Previously, the AMIS (Acute Myocardial Infarction 
in Switzerland) Plus Registry reported the incidence 
and mortality of CS in Switzerland during the period 
between 1997 and 2006.11 Since 2006, several trials 
have been published that changed treatment strategies 
and management of CS. Currently, patients are treated 
with newer generation drug-eluting stents, and the use 
of bare metal stents has declined. Early revasculariza-
tion has emerged as a standard therapy for CS. On the 
contrary, the intra-aortic balloon pump (IABP)-shock 
II trial showed a lack of survival benefit with the use 
of the IABP in patients with CS with a 40% mortality 
at 30 days and a 50% mortality at 12 months in both 
groups—IABP versus standard medical therapy.12,13 Other 
mechanical circulatory devices such as axial flow pump 
(Impella, Abiomed) or the venous-arterial extracorpo-
ral membrane oxygenation (ECMO) have emerged, 
although no large randomized trials are available sup-
porting the use of any of these devices. The recently 
published CULPRIT-shock trial failed to show a benefit 
with the multivessel treatment strategy14–16 versus the 
culprit vessel–only treatment strategy in CS.17
The AMIS Plus Registry is a Swiss nationwide cohort 
study collecting data on hospital admissions for acute 
myocardial infarction (AMI) since 1997. The aim of this 
study is first to analyze temporal trends in the incidence 
and mortality of CS over the last 20 years and to assess 
the impact of culprit versus multivessel revasculariza-
tion in this real-world registry. In addition, predictors of 




Since 1997, 83 of the 106 acute cardiac care hospitals in 
Switzerland have participated in the AMIS Plus Registry.11 All 
participating hospitals have either a catheterization laboratory 
or direct access to a center providing percutaneous coronary 
intervention (PCI) within 90 minutes for all patients.
Data Availability Statement: the authors confirm that, 
for approved reasons, some access restrictions apply to the 
data underlying the findings. Individual data used for the 
construction of the AMIS Plus Registry are property of the 
hospitals participating in the AMIS registry and may only be 
made available by each hospital’s principal investigator and 
steering committee. This also applies to derivatives such as 
the analysis files used for this study. However, after approval 
of the AMIS Plus steering committee and subsequent nego-
tiation of an individual AMIS plus module contract with the 
AMIS Plus steering committee, analysis files can be handed 
over to other researchers. Requests must be submitted to Prof 
Paul Erne (President of the AMIS Plus Steering Committee; 
paul.erne@ernenet.ch) and Dr Dragana Radovanovic (Head of 
Data Center AMIS Plus; dragana.radovanovic@uzh.ch).
Ethics
The Swiss Societies of Internal Medicine, Cardiology, and 
Intensive Care Medicine founded the AMIS Plus Registry 
project. A steering committee that includes members of the 
founding medical societies guides the project. This study com-
plied with the Declaration of Helsinki regarding investigations 
on humans and was approved by the Swiss National Ethical 
Committee for Clinical Studies, the Board for Data Security 
and all cantonal ethic committees approved the registry.
Data Collection
Investigators at participating centers collect data for the regis-
try by using identical web-based data entry systems. The case 
record form has 240 items that address medical history, car-
diovascular risk factors, symptoms, initial out-of-hospital man-
agement, clinical presentation, early in-hospital management, 
WHAT IS KNOWN
• Long-term trends of incidence and outcome of 
cardiogenic shock (CS) patients are scarce—a 
reduction in CS-associated mortality since the late 
nineties has been reported; the incidence of CS 
remained unchanged.
• Multivessel percutaneous coronary intervention is 
not recommended in CS and controversial in acute 
myocardial infarction.
WHAT THE STUDY ADDS
• We confirm a reduction of CS-associated in-hos-
pital mortality in the last 20 years from >60% in 
1997 to <40% in 2017.
• The incidence of CS developing during hospital-
ization further declined during the last 20 years, 
whereas the incidence of CS on admission increased.
• Multivessel percutaneous coronary intervention in 
acute myocardial infarction was associated with an 
































Hunziker et al; Twenty-Year Trends of Cardiogenic Shock
Circ Cardiovasc Interv. 2019;12:e007293. DOI: 10.1161/CIRCINTERVENTIONS.118.007293 April 2019 3
reperfusion therapy, hospital course, diagnostic tests used or 
planned, length of stay, and discharge medication and desti-
nation. A data coordinating center checks data for plausibility 
and consistency. Central data monitors returned incomplete 
questionnaires to the participating centers for completion 
(19% in 2003). This approach helped to minimize data loss 
and warrant a consistent data quality (<1% overall and 0% 
for therapeutic interventions).18
Patient Enrollment
Patients were enrolled in the registry if their final diagnosis 
met 1 of the 3 following criteria: AMI, defined as symptoms 
or electrocardiographic changes compatible with AMI and 
cardiac markers (either creatine kinase MB fraction at least 
twice the upper limit of normal or troponin I or T above indi-
vidual hospital cutoff levels for myocardial infarction). Cases 
of unstable angina were excluded. In this study, we included 
all patients with AMI (non-STEMI and STEMI) entered in the 
AMIS Plus Registry between January 1, 1997, and December 
31, 2017, from the participating hospitals.
Charlson Comorbidity Index was measured since 2002. 
Data for multivessel disease treatment strategies were avail-
able since 2005. Of 18 949 patients with multivessel disease 
assessed between 2005 and 2017 with AMI, 15 916 (84%) 
data with respect to multivessel versus culprit vessel treat-
ment were available. Data of Impella and ECMO usage were 
collected since 2013.
Definitions
Patients who had ST-segment elevation or new left bun-
dle branch block on their initial ECG were classified as 
ST-segment–elevation AMI. We classified patients who had 
ST-segment depression or T-wave abnormalities in the absence 
of ST-segment elevation on the initial ECG as non–ST-seg-
ment–elevation AMI. We defined CS at admission and during 
hospitalization in all participating centers by using the Killip 
definition of hypotension (systolic blood pressure <90 mm Hg) 
and evidence of hypoperfusion (oliguria, cyanosis, and cold 
extremities).19
Statistical Analysis
The results are presented as percentages for categorical vari-
ables. Data are analyzed using the nonparametric Pearson 
χ2 test or Fisher exact test where appropriate. In the case of 
missing data, instead of an imputation procedure, we provide 
the number of patients with a characteristic to number of 
patients with available data (n). Continuous normally distrib-
uted variables are expressed as means±1 SD and compared 
using the Student 2-tailed unpaired t test. Continuous non-
normally distributed variables are expressed as median and 
interquartile ranges and analyzed using the Mann-Whitney U 
test. Univariable and multivariable binary logistic regressions 
were used to analyze trends of mortality over admission years. 
Variable selection was based on prior studies, experience, and 
clinical knowledge. Explanatory variables were CS at admis-
sion, CS developing during hospitalization, age, sex, STEMI, 
and performed PCI. Model fit was assessed using the Hosmer-
Lemeshow test. The results of logistic regression are reported 
as odds ratios (ORs) with a 95% CI. A P value of <0.01 was 
considered significant. SPSS software (version 23; SPSS, Inc, 
Chicago, IL) was used for statistical analysis.
RESULTS
Patients
From January 1997 to December 2017, 52 805 patients 
with AMI were included in the AMIS Plus Registry 
(Figure 1). Four thousand ninety patients (7.7%) pre-
sented with CS, of whom 1907 patients (3.6% of 
those with AMI and 46.6% of those with CS) had CS 
on admission and 2183 patients (4.1% of those with 
AMI and 53.4% of those with CS) developed CS during 
hospitalization.
Baseline risk for cardiovascular disease (dyslipidemia, 
hypertension, diabetes mellitus, and renal disease but 
not smoking) was higher among patients with CS than 
among those without (Table  1); specifically, patients 
with CS were older, more likely to be women, and had 
a higher incidence of atrial fibrillation. The incidence of 
resuscitation was 30.1% among patients with CS com-
pared with 3.3% in patients with AMI (P<0.001).
The presence of a Charlson Comorbidity Index >1, 
was higher in the CS population compared with AMI 
patients (22.4%–35.9%; P<0.001) and also higher 
in patients who acquired CS during hospitalization 
(31.9%–40.5%; P<0.001).
Therapeutic Interventions
Patient with CS less often received immediate medical 
treatment such as aspirin, P2Y12 inhibitors, β-blocker, 
nitrate, ACE (angiotensin-converting enzyme) inhibi-
tor/ARB (angiotensin II receptor blocker), and statins 
Figure 1. Flowchart of patients included in the acute myocardial  
infarction study.  
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(Table 2). Conversely, diuretics and vasopressors agents 
were more often applied in CS patients. Coronary angi-
ography was immediately performed only in 61% of 
patients with CS (in 75.8% in CS on admission and 
48.4% in CS during hospitalization) compared with 
71.5% in the overall AMI population. A total of 27% 
of patients with CS received an IABP with no difference 
among patients who presented with CS on admission 
or developed CS during hospitalization. In summary, 
9.8% of patients received an ECMO or an axial flow 
pump device such as an Impella (data collected since 
2013). Door-to-balloon time was documented in 84% 
of patients with CS. Median time was 64 minutes 
(range, 26–135 minutes). Invasive mechanical vential-
tion was introduced in 44.6% of patients with CS and 
7.7% (data available since 2005) received non-invasive 
mechanical ventilation. In 16.5% of patients with CS, 
a hypothermia protocol (data available since 2009) was 
applied (Table 2).
Treatment of CS With Multivessel Disease 
and Predictors of Mortality
Data with respect to treatment strategies of multivessel 
disease were collected since 2005. In 15 916 of 18 949 
patients, data of multivessel disease and treatment strat-
egy were available of whom 1225 patients presented with 
a CS. In 804 (65.6%) patients, the culprit vessel only was 
treated, and in 421 (34.4%), multivessel revascularization 
was performed. There was no difference with respect to 
crude mortality whether the culprit vessel–only or multi-
vessel PCI was performed (39.1% versus 40.9% mortality; 
P=0.54; Table 2). In the CS population with multivessel 
disease (n=1225), multivariable logistic regression mod-
els including age, sex, and multivessel PCI did not reveal 
to be an independent predictor of mortality (OR, 1.12; 
95% CI, 0.89–1.44). In contrast, predictor analysis of all 
AMI patients with multivessel disease (n=15 916/18 946) 
including age, sex, STEMI, and multivessel PCI was 











Age, y; mean (SD) 65.8 (13.2) 69.6 (12.5) <0.001 67.2 (12.6) 71.7 (12.0) 0.001
Sex: female (%) 12 631/47 752 (26.5) 1263/4090 (30.9) <0.001 506/1907 (26.5) 757/2183 (34.7) <0.001
Resuscitation prior admission (%) 1569/47 549 (3.3) 1223/4059 (30.1) <0.001 959/1895 (50.6) 264/2164 (12.2) <0.001
Delay, min (symptoms on admission); 
median (IQR)
230 (115–660) 165 (84–483) <0.001 110 (67–254) 240 (115–781) <0.001
Vital signs at admission, mean (SD)
  Systolic blood pressure, mm Hg 138.4 (27.1) 111.7 (31.0) <0.001 101.3 (29.8) 120.4 (29.2) <0.001
  Diastolic blood pressure, mm Hg 80.6 (16.8) 67.4 (21.5) <0.001 62.0 (23.1) 71.8 (19.0) <0.001
  Heart rate, bpm 78.2 (19.2) 89.5 (28.2) <0.001 90.9 (30.5) 88.4 (26.0) 0.005
STEMI (%) 27 466/47 752 (57.5) 3027/4090 (74.0) <0.001 1405/1907 (73.7) 1622/2183 (74.3) 0.67
NSTEMI (%) 20 286/47 752 (42.5) 1063/4090 (26.0) <0.001 502/1907 (26.3) 561/2183 (25.7) 0.67
Killip classes n=47 419 n=4030 <0.001 n=1907 n=2123 <0.001
  Class I 39 993 (84.3) 1111 (27.6)  0 1111 (52.3)  
  Class II 5883 (12.4) 630 (15.6)  0 630 (29.7)  
  Class III 1540 (3.2) 382 (9.5)  0 382 (18.0)  
  Class IV 0 1907 (47.3)  1907 (100) 0  
Risk factors/history of the following
  Smoking (%) 17 202/43 710 (39.4) 1285/3173 (40.5) 0.21 666/1343 (49.6) 619/1830 (33.8) <0.001
  Dyslipidemia (%) 25 267/42 870 (58.9) 1681/3226 (52.1) <0.001 772/1438 (53.7) 909/1788 (50.8) 0.11
  Hypertension (%) 27 223/45 700 (59.6) 2300/3563 (64.6) <0.001 1024/1579 (64.9) 1276/1984 (64.3) 0.75
  Diabetes mellitus (%) 9121/46 045 (19.8) 1086/3634 (29.9) <0.001 465/1604 (29.0) 621/2030 (30.6) 0.31
  Obesity (%), BMI >30 8363/40 509 (20.6) 550/2928 (18.8) 0.016 236/1375 (17.2) 314/1553 (20.2) 0.037
  Coronary artery disease (%) 14 962/44 830 (33.4) 1267/3547 (35.7) 0.005 535/1679 (31.9) 732/1868 (39.2) <0.001
  Renal disease* (%) 2647/39 397 (6.7) 364/2776 (13.1) <0.001 155/1487 (10.4) 209/1289 (16.2) <0.001
  Cancer diseases* (%) 2153/39 396 (5.5) 215/2795 (7.7) <0.001 106/1506 (7.0) 109/1289 (8.5) 0.18
  Charlson Comorbidity Index >1* (%) 8826/39 396 (22.4) 996/2776 (35.9) <0.001 474/1487 (31.9) 522/1289 (40.5) <0.001
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identified as an independent predictor of mortality with 
an OR of 1.88 (95% CI, 1.59–2.21). In addition, multives-
sel PCI in AMI patients with multivessel disease was also 
an independent predictor for CS developing during hos-
pitalization (OR, 1.93; 95% CI, 1.62–2.30).
Temporal Trends
Between 1997 and 2017, rates of CS decreased from 
8.7% (1997–2006) to 7.3% (2007–2017; P<0.001; 
Figure 2). Compared with the previous time period of 
1997 to 2006, the incidence of CS developing during 
hospitalization declined from 7.8% (1997–2006) to 
3.5% (1997–2017; P<0.001), whereas the rates of CS 
on admission increased form 2.5% in 1997 to 2006 to 
4.6% (P<0.001) in 2007 to 2017.
Rates of immediate medical therapy increased in the 
decade 2007 to 2017 compared to the decade 1997 to 
2006, for aspirin from 94.2% to 96.0% (P<0.001), for 
P2Y12 from 47.5% to 87.9% (P<0.001), and for statins 
from 71.8% to 76.7% (P<0.001). Similar, rates of cor-
onary angiography and PCI increased from 40.2% in 
1997 to 2006 to 80% in the time period of 2007 to 
2017 (P<0.001). Between 2007 and 2017, the use of 
ECMO/Impella (data available since 2013) increased, 
whereas rates of IABP implantation have remained 
stable. Need for coronary artery bypass graft surgery 
(10%) and multivessel PCI (2007: 35.4% and 2017: 
33.8%; P=0.87) remained stable (Figure 3).
In-Hospital Complication and Outcome
The overall mortality in patients with CS between 1997 
and 2017 was 49.2%, with a higher mortality rate in 
patients acquiring CS during hospitalization compared 
with AMI patients with CS on admission (53.5% ver-
sus 44.4%; P<0.001; Table 3). However, mortality rate 
in all CS patients was 62.8% in 1997 and declined to 
46.8% in 2006 to 36.3% in 2017 (P <0.001 for tempo-
ral trend; Figure 4).
Table 2. Immediate Therapies (Within the First 24 Hours) of Acute Myocardial Infarction Patients According to CS (N=51,842)
n (%) No CS (n=47 752) CS (n=4090) P Value
CS at Admission 
(n=1907)
CS During 
Hospitalization (n=2183) P Value
Aspirin (%) 45611/47619 (95.8) 3559/4025 (88.5) <0.001 1642/1867 (87.9) 1917/2158 (88.8) 0.40
P2Y12 inhibitor (%) 34039/47520 (71.6) 2198/4016 (54.7) <0.001 1204/1862 (64.7) 994/2154 (46.1) <0.001
GPIIb/IIIa inhibitors (%) 10410/42595 (24.4) 810/3336 (24.3) 0.85 396/1726 (22.9) 414/1610 (25.7) 0.063
Beta blocker (%) 31127/47336 (65.8) 1260/3989 (31.6) <0.001 421/1841 (22.9) 839/2148 (39.1) <0.001
Nitrate (%) 26867/47105 (57.0) 1698/3992 (42.5) <0.001 540/1840 (29.3) 1158/2152 (53.8) <0.001
ACEI/ARB (%) 25129/47219 (53.2) 1038/3972 (26.1) <0.001 404/1833 (22.0) 634/2139 (29.6) <0.001
Calcium channel blocker (%) 4432/46957 (9.4) 189/3974 (4.8) <0.001 66/1834 (3.6) 123/2140 (5.7) 0.002
Diuretic (%) 6554/32738 (20.0) 824/2444 (33.7) <0.001 427/1464 (29.2) 397/980 (40.5) <0.001
Statin (%) 30951/40207 (77.0) 1511/3025 (50.0) <0.001 803/1670 (48.1) 708/1355 (52.3) 0.023
Vasopressor (%) 1616/32600 (5.0) 1362/2453 (55.5) <0.001 896/1475 (60.7) 466/978 (47.6) <0.001
Coronary angiography (%) 34156/47752 (71.5) 2502/4089 (61.2) <0.001 1445/1906 (75.8) 1057/2183 (48.4) <0.001
PCI (%) 33264/46860 (71.0) 2443/4030 (60.6) <0.001 1413/1874 (75.4) 1030/2156 (47.8) <0.001
IABP(%) 855/47008 (1.8) 1079/3993 (27.0) <0.001 519/1855 (28.0) 560/2138 (26.2) 0.21
ECMO/Impella (%)* 15/8488 (0.2) 74/757 (9.8) <0.001 45/481 (9.4) 29/276 (10.5) 0.61
Invasive mechanical 
ventilation (%)
1995/47319 (2.3) 1801/4035 (44.6) <0.001 933/1876 (49.7) 868/2159 (40.2) <0.001
Non-invasive mechanical 
ventilation (%)†
396/33517 (1.2) 193/2522 (7.7) <0.001 79/1510 (5.2) 114/1012) (11.3) <0.001
Cooling of body temp (%)‡ 25/4594 (0.5) 63/381 (16.5) <0.001 59/259 (22.8) 4/122 (3.3) <0.001
Culprit / Multivessel PCI











<0.001 804 (65.6%) 
421 (34.4%)











0.54 176 (37.4%) 
107 (40.4%)
0.48 138 (41.3%) 
65 (41.7%)
1.0
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotension II receptor antagonist; CS, cardiogenic shock; ECMO, extracorporal membrane 
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Rates of reinfarction (3.0% versus 10.8%; P<0.001) 
and major adverse cardiac events (47.3% versus 56.8%; 
P<0.001) were significantly lower in CS on admission 
compared with CS acquired during hospitalization. 
No difference was observed with respect to bleeding, 
cerebrovascular events, length of stay, and probable/
definitive stent thrombosis (data available since 2010; 
Table 3).
Independent Predictors of In-Hospital 
Mortality in CS
In CS (n=4090), patients’ age per additional year (OR, 
1.04; 95% CI, 1.03–1.05), Charlson Comborbidity 
Index >1 (OR, 1.36; 95% CI, 1.09–1.70), and lack of 
PCI (OR, 2.80; 95% CI, 2.22–3.53) were independent 
predictors of in-hospital mortality; sex, STEMI, diabetes 
mellitus, hypertension, and dyslipidemia were not.
Analysis of the entire AMI population (n=51 841; refer-
ence, no CS), CS at admission (OR, 43.1; 95% CI, 38.1–
48.8; P<0.001), CS developing during in-hospital (OR, 
36.8; 95% CI, 32.9–41.2; P<0.001), age per additional 
year (OR, 1.06; 95% CI, 1.06–1.07; P<0.001), STEMI (OR, 
1.30; 95% CI, 1.18–1.43; P<0.001), and lack of PCI (OR, 
3.05; 95% CI, 2.77–3.36; P<0.001) appeared as indepen-
dent predictors of in-hospital mortality (Table 4).
DISCUSSION
In this analysis of a large, population-based registry 
covering 20 years of observation, rates of CS on admis-
sion increased during the last decade. In contrast, the 
trend of decreasing numbers of patients developing 
CS during hospitalization continued. Rates of PCI in 
CS further increased to 80% (2007–2017), compared 
with 40.2% in the previous time period of 1997 to 
2006. Similarly, medical treatment with statins and 
P2Y12 inhibitors increased. Mortality declined from 
62.2% in 1997 to <40% in 2017. We postulate that 
the increasing incidence of CS on admission is related 
to improvements in acute myocardial infarction net-
work and medical care over the last 20 years leading to 
more frequent and rapid transportation of even sicker 
patients, who would otherwise have died before arriv-
ing at the hospital. In addition, the decreasing inci-
dence of CS developed during hospitalization might 
be due to an earlier arrival at the hospital and an 
increased usage of PCI with reduction in infarct size.
Figure 2. Trends in the incidence of overall 
cardiogenic shock (CS), CS at admission, 
and CS developing during hospitalization 
in patients with acute myocardial infarction 
(AMI; n=51 842).  
Percentage in the table indicates percentage of 
overall CS. Dotted lines indicate trendlines.
Figure 3. Trends in use of multivessel 
percutaneous coronary intervention (PCI); 
coronary artery bypass graft (CABG), intra-
aortic balloon pump (IABP), and Impella/
extracorporal membrane oxygenation 
(ECMO) in patients with acute myocardial 
infarction with cardiogenic shock.  
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Since the inclusion of multivessel intervention as 
parameter in the AMIS registry in 2003, the use of mul-
tivessel PCI in patients with CS and multivessel disease 
remained stable in approximately one-third of patients. 
We were unable to show a beneficial effect in terms of 
mortality among patients with CS undergoing multives-
sel PCI compared with culprit-only intervention. In the 
multivariable logistic regression model including only CS 
patients with multivessel disease (n=1225), multivessel PCI 
was not an independent predictor of in-hospital mortality 
(OR, 1.12). However, if patients with AMI and multives-
sel disease (n=15 916) were analyzed together, multivessel 
PCI emerged as an independent predictor of in-hospital 
mortality with an OR of 1.88. Furthermore, AMI patients 
with multivessel disease and multivessel PCI, compared 
with culprit lesion–only PCI, more frequently developed 
CS during hospitalization (OR, 1.93). This finding is in 
line with the results of the CULPRIT-shock trial,17 whereas 
higher mortality and need for renal replacement therapy 
was observed in the multivessel PCI group. Multivessel PCI 
in patients with AMI might even be one of the factors 
influencing the development of CS during hospitalization.
After publication of the IABP-shock II trial in 2012,13 
a numerical decrease in IABP use has been observed. 
In 2007 to 2013, 110 of 267 patients received an IABP 
(41.2%), whereas between 2014 and 2017, there 
were 37 of 96 patients who were treated with an IABP 
(38.5%; P=0.76). In parallel, there was an increased use 
of other mechanical circulatory devices such as vaECMO 
and Impella (Figure 3). Meanwhile, mortality declined 
from 47.3% in 2007 to 2013 (653 of 1380 patients) to 
41.0% in 2014 to 2017 (305 of 743 patients; P=0.006). 
However, the collected data of vaECMO and axial 
flow pump (Impella) insertion in CS are incomplete. A 
detailed analysis is, therefore, not included in the cur-
rent study, and we are not able to draw conclusion with 
respect to the influence of temporary mechanical circu-
latory devices on in-hospital mortality in recent years.
Independent predictors of in-hospital mortality 
remained unchanged compared with the previously 
analyzed period.11 In the CS population, age, comor-
bidity (Charlson comborbidity index >1), and lack of PCI 
are associated with increased mortality. In the overall 
AMI population, predictors of mortality include CS (on 
Figure 4. Trends in in-hospital mortality of 
patients with acute myocardial infarction 
according to cardiogenic shock (CS).  
Percentage in the table indicates percentage of 
overall CS. Dotted lines indicate trendlines.
Table 3. Complications and Outcome in Hospital of Patients With Acute Myocardial Infarction
No CS (n=47 752) CS (n=4090) P Value





Length of stay, d; median (IQR) 5 (2–9) 5 (1–13) 0.001 5 (1–12) 5 (1–15) 0.13
Reinfarction (%) 558/47 721 (1.2) 288/4008 (7.2) <0.001 56/1863 (3.0) 232/2145 (10.8) <0.001
Bleeding, any (%) 932/33 808 (2.8) 169/2552 (6.6) <0.001 88/1533 (5.7) 81/1019 (7.9) 0.034
Cerebrovascular event (%) 326/47 549 (0.7) 134/4015 (3.3) <0.001 75/1863 (4.0) 59/2152 (2.7) 0.027
Mortality (%) 1268/47 752 (2.7) 2014/4090 (49.2) <0.001 847/1907 (44.4) 1167/2183 (53.5) <0.001
MACE (%) 1924/47 531 (4.0) 2089/3988 (52.4) <0.001 880/1861 (47.3) 1209/2127 (56.8) <0.001
Stent thrombosis (%), probable/
definitive*
417/13 506 (3.1) 33/1074 (3.1) 0.99 19/682 (2.8) 14/392 (3.6) 0.47
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admission and developed during hospitalization), age, 
STEMI, and PCI.
Study Limitations
This study has several limitations.11,20 The AMIS 
Plus Registry represents a high-risk cohort with an 
ST-segment–elevation AMI rate of >70%. Enrollment 
was not limited to patients with CS due to left ventricu-
lar failure but included all types of CS (eg, mechanical 
complication, right heart failure). As a general limitation 
of all registries, no central review of shock diagnoses 
was performed. However, CS was defined before the 
start of this registry.19,21 These definitions were provided 
to the investigators in both the written and online case 
record forms, and the definitions used did not change 
during the study period. As with all nonrandomized 
data, we cannot exclude possible selection bias, con-
founding by indication, and residual confounding. No 
causal relationship can be established, and interactions 
among various residual unknown predictors of out-
comes cannot be tested. Finally, follow-up time was 
limited to the hospital stay.
Conclusions
During the past decade, rates of CS on admission have 
increased, whereas rates of CS developing during hos-
pitalization further decreased. Rates of revasculariza-
tion by means of PCI have increased substantially from 
40.2% in 1997 to 2006 to 80% in the time period 
of 2007 to 2017. Use of multivessel revascularization 
strategies in the CS population compared with culprit 
vessel–only PCI had no impact on in-hospital mortal-
ity in the CS population. However, multivessel PCI 
emerged as an independent predictor of in-hospital 
mortality and CS developing during hospitalization in 
the overall AMI population.
We can postulate that improvements in medical 
management, especially the increase of immediate PCI, 
relate to the observed reduction of CS development 
during hospitalization and the lower mortality rates 
among patients with CS in general.
Although a clear reduction of cardiogenic associated 
mortality was achieved in the last 20 years, fatal out-
come remains high. There remains an important need 
for better therapeutic options and the need for ran-
domized trials with respect of the utility of temporary 
mechanical circulatory device support.
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universitaires (M. Roffi); Glarus, Kantonsspital (W. Wojtyna); Grenchen, Spital 
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(H. Marty); Kreuzlingen, Herzzentrum Bodensee (K. Weber); La Chaux-de-Fonds, 
Table 4. Multivariable Logistic Regression Analyses
Variables OR 95% CI P Value
CS at admission (no CS=reference) 43.1 38.1–48.8 <0.001
CS developing in hospital 36.8 32.9–41.2 <0.001
Age per additional year 1.06 1.06–1.07 <0.001
Female sex 1.04 0.95–1.14 0.42
STEMI 1.30 1.18–1.43 <0.001
No PCI 3.05 2.77–3.36 <0.001
Independent predictors of in-hospital mortality (n=51 841). CS indicates 
cardiogenic shock; OR, odds ratio; PCI, percutaneous coronary intervention; 
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Kantonsspital (F. Widmer); Muri, Kreisspital für das Freiamt (C. Heimgartner); 
Nyon, Group. Hosp. Ouest lémanique (R. Polikar); Olten, Kantonsspital (S. 
Bassetti); Rheinfelden, Gesundheitszentrum Fricktal (H.U. Iselin); Rorschach, 
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Limmattal (T. Herren); Schwyz, Spital (P. Eichhorn); Scuol, Ospidal d’Engiadina 
Bassa (C. Neumeier/G. Flury); Sion, Hôpital du Valais (G. Girod); Solothurn, 
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Kantonsspital (H. Rickli); Sursee, Luzerner Kantonsspital (S. Yoon, J. Nossen); 
Thun, Spital (U. Stoller); Thusis, Krankenhaus (U.P. Veragut); Uster, Spital 
(E. Bächli); Uznach, Spital Linth (A. Weber); Walenstadt, Kantonales Spital 
(D. Schmidt/J. Hellermann); Wetzikon, GZO Spital (U. Eriksson); Winterthur, 
Kantonsspital (T. Fischer); Wolhusen, Luzener Kantonsspital (M. Peter); Zofingen, 
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